0001564590-22-015520.txt : 20220426 0001564590-22-015520.hdr.sgml : 20220426 20220426081518 ACCESSION NUMBER: 0001564590-22-015520 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220425 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220426 DATE AS OF CHANGE: 20220426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH SERVICES INC CENTRAL INDEX KEY: 0000352915 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 232077891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10765 FILM NUMBER: 22851854 BUSINESS ADDRESS: STREET 1: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 6107683300 MAIL ADDRESS: STREET 1: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 8-K 1 uhs-8k_20220425.htm 8-K uhs-8k_20220425.htm
false 0000352915 0000352915 2022-04-25 2022-04-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2022

 

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

1-10765

 

23-2077891

(State or other jurisdiction of

 

(Commission

 

(I.R.S. Employer

Incorporation or Organization)

 

File Number)

 

Identification No.)

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania 19406

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class B Common Stock

UHS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 


 

 

Item 2.02 Results of Operations and Financial Condition

On April 25, 2022, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

 

 

99.1

  

Universal Health Services, Inc., press release, dated April 25, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

Exhibit Index

 

Exhibit No.

  

Exhibit

 

 

99.1

  

Universal Health Services, Inc., press release, dated April 25, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Universal Health Services, Inc.

 

By:

 

/s/ Steve Filton

Name: Steve Filton

Title: Executive Vice President and

            Chief Financial Officer

Date: April 26, 2022

 

 

 

 

EX-99.1 2 uhs-ex991_6.htm EX-99.1 uhs-ex991_6.htm

 

Exhibit 99.1

FOR IMMEDIATE RELEASE

April 25, 2022

 

CONTACT:

Steve Filton

 

Chief Financial Officer

 

610-768-3300

 

 

UNIVERSAL HEALTH SERVICES, INC.

ANNOUNCES 2022 FIRST QUARTER FINANCIAL RESULTS

 

Consolidated Results of Operations, As Reported and As Adjusted  – Three-month periods ended March 31, 2022 and 2021:

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $153.9 million, or $2.02 per diluted share, during the first quarter of 2022, as compared to $209.1 million, or $2.43 per diluted share, during the first quarter of 2021. Net revenues increased by 9.3% to $3.293 billion during the first quarter of 2022 as compared to $3.013 billion during the first quarter of 2021.

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the first quarter of 2022 was $163.5 million, or $2.15 per diluted share, as compared to $210.1 million, or $2.44 per diluted share, during the first quarter of 2021.  

As reflected on the Supplemental Schedule, included in our reported results during the first quarter of 2022, was an unfavorable after-tax unrealized loss of $9.5 million, or $.13 per diluted share, ($12.5 million pre-tax which is included in “Other (income) expense, net”), resulting from a decrease in the market value of certain equity securities.  

As reflected on the Supplemental Schedule, included in our reported results during the first quarter of 2021, was a net aggregate unfavorable after-tax impact of $1.1 million, or $.01 per diluted share, consisting of the following: (i) an after-tax unrealized loss of $2.1 million, or $.02 per diluted share, ($2.8 million pre-tax which is included in “Other (income) expense, net”), resulting from a decrease in the market value of certain equity securities, and; (ii) a favorable after-tax impact of $1.1 million, or $.01 per diluted share, resulting from ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”).

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $368.3 million during the first quarter of 2022, as compared to $426.3 million during the first quarter of 2021. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $379.5 million during the first quarter of 2022, as compared to $427.1 million during the first quarter of 2021.

Acute Care Services – Three-month periods ended March 31, 2022 and 2021:

During the first quarter of 2022, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 5.7% and adjusted patient days increased by 5.5%, as compared to the first quarter of 2021. At these facilities, during the first quarter of 2022, net revenue per adjusted admission increased by 3.1% and net revenue per adjusted patient day increased by 3.3%, as compared to the first quarter of 2021. Net revenues generated from our acute care services on a same facility basis increased by 9.7% during the first quarter of 2022, as compared to the first quarter of 2021.  

 


 

Behavioral Health Care Services – Three-month periods ended March 31, 2022 and 2021:

During the first quarter of 2022, at behavioral health care facilities on a same facility basis, adjusted admissions decreased by 1.9% and adjusted patient days decreased by 1.3%, as compared to the first quarter of 2021. At these facilities, during the first quarter of 2022, net revenue per adjusted admission increased by 5.8% and net revenue per adjusted patient day increased by 5.1%, as compared to the first quarter of 2021.  Net revenues generated from our behavioral health care services increased by 3.8% during the first quarter of 2022, as compared to the first quarter of 2021.

COVID-19

The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material effect on our operations and financial results since that time. The COVID-19 vaccination process commenced during the first quarter of 2021. Since that time through the second quarter of 2021, we had generally experienced a decline in COVID-19 patients as well as a corresponding recovery in non-COVID patient activity.  However, during the third and fourth quarters of 2021, and continuing into the early part of the first quarter of 2022, our facilities generally experienced an increase in COVID-19 patients resulting from the Delta and, more recently, the highly transmissible Omicron variants. COVID-19 related patient volumes at our facilities were generally declining during the latter part of the first quarter of 2022.  

The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. Like others in the healthcare industry, we continue to experience a shortage of nurses and other clinical staff and support personnel at our acute care and behavioral health care hospitals in many geographic areas. In some areas, the labor scarcity is putting a strain on our resources and staff, which has required us to utilize higher‑cost temporary labor and pay premiums above standard compensation for essential workers. This staffing shortage has required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, we have been unable to fill all vacant positions and, consequently, have been required to limit patient volumes. These factors had a material unfavorable impact on our results of operations during the first quarter of 2022. The length and extent of the disruptions caused by the COVID‑19 pandemic are currently unknown; however, we expect such disruptions to continue during 2022.

Since the future volumes and severity of COVID-19 patients remain highly uncertain and subject to change, including potential increases in future COVID-19 patient volumes caused by new variants of the virus, as well as related pressures on staffing and wage rates, we are not able to fully quantify the impact that these factors will have on our future financial results.  However, developments related to the COVID-19 pandemic could continue to materially affect our financial performance during 2022.  

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

For the three months ended March 31, 2022, our net cash provided by operating activities was $445 million as compared to $72 million during the first quarter of 2021.  The $374 million net increase in our net cash provided by operating activities during the first quarter of 2022, as compared to the first quarter of 2021, was due to: (i) a favorable change of $510 million resulting primarily from the early return of Medicare accelerated payments which were received during 2020 and repaid during the first quarter of 2021, partially offset by; (ii) an unfavorable change of $72 million in accounts receivable; (iii) an unfavorable change of $44 million resulting from a decrease in net income plus depreciation and amortization expense, stock-based compensation expense and gain/loss on sales of assets and businesses, and; (iv) $20 million of other combined net unfavorable changes.    

Liquidity:

 


 

As of March 31, 2022, we had $736 million of aggregate available borrowing capacity pursuant to our $1.2 billion revolving credit facility, net of outstanding borrowings and letters of credit.  

Stock Repurchase Program:

As previously announced, on February 24, 2022, our Board of Directors authorized a $1.4 billion increase to our stock repurchase program. Pursuant to this program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions. 

During the first quarter of 2022, we have repurchased approximately 2.65 million shares at an aggregate cost of approximately $350.2 million (approximately $132 per share).  As of March 31, 2022, we had an aggregate available repurchase authorization of approximately $1.41 billion.  

2022 Operating Results Forecast:

On February 24, 2022, we provided our 2022 operating results forecast as part of our 2021 fourth quarter and full year financial results’ announcement.  As disclosed at that time, since the future volumes and severity of COVID-19 patients remain highly uncertain and subject to change, as well as pressures on staffing and wage rates, we are not able to fully quantify the impact that these factors will have on our future financial results.  

Our operating results during the first quarter of 2022 reflect continued uncertainties related to the COVID-19 pandemic as well cost escalations related to the nationwide shortage of nurses and other clinical staff and support personnel.  As a result, our labor costs were higher than anticipated, and patient volumes at our behavioral health care facilities were lower than anticipated, which unfavorably impacted our operating results during the first quarter of 2022.

At this time, we are not changing our previously released 2022 operating results forecast.  However, given the continued uncertainties related to the COVID-19 pandemic, as well as the healthcare staffing shortage and its unfavorable impact on our labor costs and behavioral health patient volumes, we may make reductions to our 2022 full year operating results forecast at a future date if the unfavorable operating trends experienced during the first quarter of 2022 do not improve.      

Conference call information:        

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on April 26, 2022. The dial-in number is 1-877-648-7971.  

A live broadcast of the conference call will be available on our website at www.uhs.com.  Also, a replay of the call will be available following the conclusion of the live call and will be available for one full year.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2021 were approximately $12.6 billion. In 2022, UHS was again recognized as one of the World’s Most Admired Companies by Fortune; and in 2021 the Company ranked #270 on the Fortune 500 and #307 on Forbes’ list of America’s Largest Public Companies.

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.  Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has over 89,000 employees and through its subsidiaries operates 28 acute care hospitals (including the newly constructed, 170-bed Northern Nevada Sierra Medical Center located in Reno, Nevada, which opened in early April, 2022), 336 behavioral health facilities, 40

 


 

outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 U.S. states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).  For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations.  Numerous factors, including those disclosed herein, those related to the anticipated impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors and in Item 7-Forward-Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2021), may cause the results to differ materially from those anticipated in the forward-looking statements.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof.  We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  Many of the factors that could affect our future results are beyond our control or ability to predict, including the impact of the COVID-19 pandemic. Our future operations and financial results will likely be materially impacted by developments related to COVID-19 including, but not limited to, the potential impact on future COVID-19 patient volumes resulting from new variants of the virus, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated at our hospitals and other healthcare facilities; measures we are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation and stimulus on the hospital industry and potential retrospective adjustment in future periods of CARES Act and other grant income revenues recorded as revenues in prior periods; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to our clinical staffing and shortages and disruptions related to supplies required for our employees and patients; potential increases to expenses and other costs related to staffing, supply chain, construction and medical equipment costs and other expenditures resulting from inflation; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in our markets resulting from the COVID-19 pandemic. We are not able to fully quantify the impact that these factors will have on our future financial results, but developments related to the COVID-19 pandemic could continue to materially affect our financial performance during 2022.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2021. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these

 


 

measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

 

(more)

 


 


 

 

 

 

Universal Health Services, Inc.

 

Consolidated Statements of Income

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Three months

 

 

 

ended March 31,

 

 

 

2022

 

 

2021

 

Net revenues

 

$

3,292,956

 

 

 

3,012,987

 

 

 

 

 

 

 

 

 

 

Operating charges:

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

1,692,270

 

 

 

1,497,773

 

Other operating expenses

 

 

820,934

 

 

 

709,708

 

Supplies expense

 

 

371,073

 

 

 

347,110

 

Depreciation and amortization

 

 

143,784

 

 

 

131,403

 

Lease and rental expense

 

 

32,038

 

 

 

31,324

 

 

 

 

3,060,099

 

 

 

2,717,318

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

232,857

 

 

 

295,669

 

Interest expense, net

 

 

21,673

 

 

 

21,957

 

Other (income) expense, net

 

 

11,201

 

 

 

835

 

Income before income taxes

 

 

199,983

 

 

 

272,877

 

Provision for income taxes

 

 

48,962

 

 

 

63,807

 

Net income

 

 

151,021

 

 

 

209,070

 

Less:  Net income (loss) attributable to noncontrolling interests ("NCI")

 

 

(2,892

)

 

 

(21

)

Net income attributable to UHS

 

$

153,913

 

 

$

209,091

 

 

 

 

 

 

 

 

 

 

Basic earnings per share attributable to UHS (a)

 

$

2.05

 

 

$

2.46

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to UHS (a)

 

$

2.02

 

 

$

2.43

 

 


 


 

 

Universal Health Services, Inc.

 

Footnotes to Consolidated Statements of Income

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Three months

 

 

 

ended March 31,

 

 

 

2022

 

 

2021

 

(a) Earnings per share calculation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted:

 

 

 

 

 

 

 

 

Net income attributable to UHS

 

$

153,913

 

 

$

209,091

 

Less: Net income attributable to unvested restricted share grants

 

 

(249

)

 

 

(552

)

Net income attributable to UHS - basic and diluted

 

$

153,664

 

 

$

208,539

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares - basic

 

 

75,030

 

 

 

84,782

 

 

 

 

 

 

 

 

 

 

Basic earnings per share attributable to UHS:

 

$

2.05

 

 

$

2.46

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares

 

 

75,030

 

 

 

84,782

 

Add: Other share equivalents

 

 

1,011

 

 

 

1,014

 

Weighted average number of common shares and equiv. - diluted

 

 

76,041

 

 

 

85,796

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to UHS:

 

$

2.02

 

 

$

2.43

 

 

 


 

 

Universal Health Services, Inc.

 

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")

 

For the Three Months ended March 31, 2022 and 2021

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

% Net

 

 

Three months ended

 

 

% Net

 

 

March 31, 2022

 

 

revenues

 

 

March 31, 2021

 

 

revenues

 

Net income attributable to UHS

$

153,913

 

 

 

 

 

 

$

209,091

 

 

 

 

 

   Depreciation and amortization

 

143,784

 

 

 

 

 

 

 

131,403

 

 

 

 

 

   Interest expense, net

 

21,673

 

 

 

 

 

 

 

21,957

 

 

 

 

 

   Provision for income taxes

 

48,962

 

 

 

 

 

 

 

63,807

 

 

 

 

 

EBITDA net of NCI

$

368,332

 

 

 

11.2

%

 

$

426,258

 

 

 

14.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

11,201

 

 

 

 

 

 

 

835

 

 

 

 

 

Adjusted EBITDA net of NCI

$

379,533

 

 

 

11.5

%

 

$

427,093

 

 

 

14.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenues

$

3,292,956

 

 

 

 

 

 

$

3,012,987

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Adjusted Net Income Attributable to UHS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

March 31, 2022

 

 

March 31, 2021

 

 

 

 

 

 

Per

 

 

 

 

 

 

Per

 

 

Amount

 

 

Diluted Share

 

 

Amount

 

 

Diluted Share

 

Net income attributable to UHS

$

153,913

 

 

$

2.02

 

 

$

209,091

 

 

$

2.43

 

Plus/minus after-tax adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on equity securities

 

9,537

 

 

 

0.13

 

 

 

2,137

 

 

 

0.02

 

Impact of ASU 2016-09

 

-

 

 

 

-

 

 

 

(1,079

)

 

 

(0.01

)

Subtotal adjustments

 

9,537

 

 

 

0.13

 

 

 

1,058

 

 

 

0.01

 

Adjusted net income attributable to UHS

$

163,450

 

 

$

2.15

 

 

$

210,149

 

 

$

2.44

 

 

 

 

 

 

 

 

 


 

 

Universal Health Services, Inc.

 

Consolidated Statements of Comprehensive Income

 

(in thousands)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Three months

 

 

 

ended March 31,

 

 

 

2022

 

 

2021

 

Net income

 

$

151,021

 

 

$

209,070

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(18,470

)

 

 

(10,346

)

Other comprehensive income (loss)  before tax

 

 

(18,470

)

 

 

(10,346

)

Income tax expense (benefit) related to items of other comprehensive income (loss)

 

 

(944

)

 

 

(1,466

)

Total other comprehensive income (loss), net of tax

 

 

(17,526

)

 

 

(8,880

)

 

 

 

 

 

 

 

 

 

Comprehensive income

 

 

133,495

 

 

 

200,190

 

Less: Comprehensive income (loss) attributable to noncontrolling interests

 

 

(2,892

)

 

 

(21

)

Comprehensive income attributable to UHS

 

$

136,387

 

 

$

200,211

 

 

 


 

 

Universal Health Services, Inc.

 

Condensed Consolidated Balance Sheets

 

(in thousands)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

105,999

 

 

$

115,301

 

Accounts receivable, net

 

 

1,754,877

 

 

 

1,746,635

 

Supplies

 

 

208,302

 

 

 

206,839

 

Other current assets

 

 

232,724

 

 

 

194,781

 

Total current assets

 

 

2,301,902

 

 

 

2,263,556

 

 

 

 

 

 

 

 

 

 

Property and equipment

 

 

10,929,292

 

 

 

10,770,702

 

Less: accumulated depreciation

 

 

(5,010,825

)

 

 

(4,896,427

)

 

 

 

5,918,467

 

 

 

5,874,275

 

Other assets:

 

 

 

 

 

 

 

 

Goodwill

 

 

3,949,788

 

 

 

3,962,624

 

Deferred income taxes

 

 

47,549

 

 

 

45,707

 

Right of use assets-operating leases

 

 

368,921

 

 

 

367,477

 

Deferred charges

 

 

6,310

 

 

 

6,525

 

Other

 

 

551,509

 

 

 

573,379

 

Total Assets

 

$

13,144,446

 

 

$

13,093,543

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Current maturities of long-term debt

 

$

48,486

 

 

$

48,409

 

Accounts payable and other liabilities

 

 

1,976,389

 

 

 

1,860,496

 

Operating lease liabilities

 

 

65,607

 

 

 

64,484

 

Federal and state taxes

 

 

55,734

 

 

 

10,720

 

Total current liabilities

 

 

2,146,216

 

 

 

1,984,109

 

 

 

 

 

 

 

 

 

 

Other noncurrent liabilities

 

 

475,006

 

 

 

464,759

 

Operating lease liabilities noncurrent

 

 

305,643

 

 

 

304,624

 

Long-term debt

 

 

4,250,689

 

 

 

4,141,879

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

4,314

 

 

 

5,119

 

 

 

 

 

 

 

 

 

 

UHS common stockholders' equity

 

 

5,867,872

 

 

 

6,089,664

 

Noncontrolling interest

 

 

94,706

 

 

 

103,389

 

Total equity

 

 

5,962,578

 

 

 

6,193,053

 

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Equity

 

$

13,144,446

 

 

$

13,093,543

 

 

 


 

 

Universal Health Services, Inc.

 

Consolidated Statements of Cash Flows

 

(in thousands)

 

(unaudited)

 

 

Three months

 

 

ended March 31,

 

 

2022

 

 

2021

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

Net income

$

151,021

 

 

$

209,070

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation & amortization

 

143,784

 

 

 

131,403

 

Loss on sale of assets and businesses

 

1,084

 

 

 

0

 

Stock-based compensation expense

 

19,055

 

 

 

18,022

 

Changes in assets & liabilities, net of effects from acquisitions and dispositions:

 

 

 

 

 

 

 

Accounts receivable

 

(15,073

)

 

 

56,851

 

Accrued interest

 

180

 

 

 

10,133

 

Accrued and deferred income taxes

 

47,548

 

 

 

53,769

 

Other working capital accounts

 

63,308

 

 

 

82,663

 

Medicare accelerated payments and deferred CARES Act and other grants

 

250

 

 

 

(509,448

)

Other assets and deferred charges

 

26,042

 

 

 

(17

)

Other

 

(4,020

)

 

 

2,623

 

Accrued insurance expense, net of commercial premiums paid

 

41,685

 

 

 

35,467

 

Payments made in settlement of self-insurance claims

 

(29,431

)

 

 

(18,741

)

Net cash provided by operating activities

 

445,433

 

 

 

71,795

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

Property and equipment additions

 

(200,002

)

 

 

(247,459

)

Proceeds received from sales of assets and businesses

 

10,232

 

 

 

0

 

Inflows (outflows) from foreign exchange contracts that hedge our net U.K. investment

 

20,710

 

 

 

(14,264

)

Decrease in capital reserves of commercial insurance subsidiary

 

100

 

 

 

100

 

Costs incurred for purchase of information technology applications, net of refunds

 

0

 

 

 

(575

)

Investment in, and advances to, joint venture and other

 

0

 

 

 

(129

)

Net cash used in investing activities

 

(168,960

)

 

 

(262,327

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

Repayments of long-term debt

 

(11,966

)

 

 

(251,830

)

Additional borrowings

 

117,400

 

 

 

0

 

Repurchase of common shares

 

(365,505

)

 

 

(7,464

)

Dividends paid

 

(14,875

)

 

 

(17,018

)

Issuance of common stock

 

3,503

 

 

 

3,357

 

Profit distributions to noncontrolling interests

 

(5,289

)

 

 

(4,525

)

Purchase (sale) of ownership interests by (from) minority member

 

(1,307

)

 

 

7,603

 

Net cash used in financing activities

 

(278,039

)

 

 

(269,877

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

(2,232

)

 

 

423

 

Decrease in cash, cash equivalents and restricted cash

 

(3,798

)

 

 

(459,986

)

Cash, cash equivalents and restricted cash, beginning of period

 

178,934

 

 

 

1,279,154

 

Cash, cash equivalents and restricted cash, end of period

$

175,136

 

 

$

819,168

 

Supplemental Disclosures of Cash Flow Information:

 

 

 

 

 

 

 

Interest paid

$

20,388

 

 

$

11,421

 

Income taxes paid, net of refunds

$

4,423

 

 

$

8,654

 

Noncash purchases of property and equipment

$

90,730

 

 

$

60,124

 

 

 


 

 

Universal Health Services, Inc.

Supplemental Statistical Information

(unaudited)

 

 

 

 

 

 

 

% Change

Same Facility:

 

 

 

 

 

3 months ended

 

 

 

 

 

 

3/31/2022

Acute Care Services

 

 

 

Revenues

 

 

9.7%

Adjusted Admissions

 

 

5.7%

Adjusted Patient Days

 

 

5.5%

Revenue Per Adjusted Admission

 

 

3.1%

Revenue Per Adjusted Patient Day

 

 

3.3%

 

 

 

 

 

 

 

Behavioral Health Care Services

 

 

 

Revenues

 

 

3.8%

Adjusted Admissions

 

 

-1.9%

Adjusted Patient Days

 

 

-1.3%

Revenue Per Adjusted Admission

 

 

5.8%

Revenue Per Adjusted Patient Day

 

 

5.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

UHS Consolidated

 

 

 

Three months ended

 

 

 

 

3/31/2022

 

3/31/2021

Revenues

 

 

 

$3,292,956

 

$3,012,987

EBITDA net of NCI

 

 

 

$368,332

 

$426,258

EBITDA Margin net of NCI

 

 

 

11.2%

 

14.1%

Adjusted EBITDA net of NCI

 

 

 

$379,533

 

$427,093

Adjusted EBITDA Margin net of NCI

 

 

 

11.5%

 

14.2%

 

 

 

 

 

 

 

Cash Flow From Operations

 

 

 

$445,433

 

$71,795

Days Sales Outstanding

 

 

 

48

 

50

Capital Expenditures

 

 

 

$200,002

 

$247,459

 

 

 

 

 

 

 

Debt

 

 

 

$4,299,175

 

$3,613,103

UHS' Shareholders Equity

 

 

 

$5,867,872

 

$6,513,862

Debt / Total Capitalization

 

 

 

42.3%

 

35.7%

Debt / EBITDA net of NCI (1) (2)

 

 

 

2.32

 

1.87

Debt / Adjusted EBITDA net of NCI (1) (2)

 

 

 

2.32

 

1.87

Debt / Cash From Operations (1) (2)

 

 

 

3.42

 

1.87

 

 

 

 

 

 

 

(1) Latest 4 quarters

 

 

 

(2) For the three months ended March 31, 2021, Debt, net of approximately $749 million of short-term cash

investments, resulted in ratios of 1.48 for each of Net Debt/EBITDA net of NCI, Net Debt/Adjusted EBITDA

net of NCI, and Net Debt/Cash from Operations.


 


 

 

Universal Health Services, Inc.

Acute Care Hospital Services

For the Three Months ended

March 31, 2022 and 2021

(in thousands)

 

Same Facility Basis - Acute Care Hospital Services

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

 

March 31, 2022

 

 

March 31, 2021

 

 

 

Amount

 

 

% of Net

Revenues

 

 

Amount

 

 

% of Net

Revenues

 

Net revenues

 

$

1,834,779

 

 

 

100.0

%

 

$

1,671,836

 

 

 

100.0

%

Operating charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

820,210

 

 

 

44.7

%

 

 

706,811

 

 

 

42.3

%

Other operating expenses

 

 

437,477

 

 

 

23.8

%

 

 

393,207

 

 

 

23.5

%

Supplies expense

 

 

313,137

 

 

 

17.1

%

 

 

296,478

 

 

 

17.7

%

Depreciation and amortization

 

 

92,939

 

 

 

5.1

%

 

 

81,184

 

 

 

4.9

%

Lease and rental expense

 

 

17,715

 

 

 

1.0

%

 

 

20,112

 

 

 

1.2

%

Subtotal-operating expenses

 

 

1,681,478

 

 

 

91.6

%

 

 

1,497,792

 

 

 

89.6

%

Income from operations

 

 

153,301

 

 

 

8.4

%

 

 

174,044

 

 

 

10.4

%

Interest expense, net

 

 

638

 

 

 

0.0

%

 

 

246

 

 

 

0.0

%

Other (income) expense, net

 

 

201

 

 

 

0.0

%

 

 

-

 

 

 

-

 

Income before income taxes

 

$

152,462

 

 

 

8.3

%

 

$

173,798

 

 

 

10.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

All Acute Care Hospital Services

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

 

March 31, 2022

 

 

March 31, 2021

 

 

 

Amount

 

 

% of Net

Revenues

 

 

Amount

 

 

% of Net

Revenues

 

Net revenues

 

$

1,912,316

 

 

 

100.0

%

 

$

1,694,542

 

 

 

100.0

%

Operating charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

843,906

 

 

 

44.1

%

 

 

707,218

 

 

 

41.7

%

Other operating expenses

 

 

482,078

 

 

 

25.2

%

 

 

416,007

 

 

 

24.5

%

Supplies expense

 

 

321,427

 

 

 

16.8

%

 

 

296,479

 

 

 

17.5

%

Depreciation and amortization

 

 

94,534

 

 

 

4.9

%

 

 

81,362

 

 

 

4.8

%

Lease and rental expense

 

 

20,852

 

 

 

1.1

%

 

 

20,112

 

 

 

1.2

%

Subtotal-operating expenses

 

 

1,762,797

 

 

 

92.2

%

 

 

1,521,178

 

 

 

89.8

%

Income from operations

 

 

149,519

 

 

 

7.8

%

 

 

173,364

 

 

 

10.2

%

Interest expense, net

 

 

638

 

 

 

0.0

%

 

 

246

 

 

 

0.0

%

Other (income) expense, net

 

 

201

 

 

 

0.0

%

 

 

-

 

 

 

-

 

Income before income taxes

 

$

148,680

 

 

 

7.8

%

 

$

173,118

 

 

 

10.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2021.

 

The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.

 


 


 

 

Universal Health Services, Inc.

Behavioral Health Care Services

For the Three Months ended

March 31, 2022 and 2021

(in thousands)

 

Same Facility - Behavioral Health Care Services

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

 

March 31, 2022

 

 

March 31, 2021

 

 

 

Amount

 

 

% of Net

Revenues

 

 

Amount

 

 

% of Net

Revenues

 

Net revenues

 

$

1,334,532

 

 

 

100.0

%

 

 

1,285,977

 

 

 

100.0

%

Operating charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

745,806

 

 

 

55.9

%

 

 

698,228

 

 

 

54.3

%

Other operating expenses

 

 

265,691

 

 

 

19.9

%

 

 

244,365

 

 

 

19.0

%

Supplies expense

 

 

49,597

 

 

 

3.7

%

 

 

50,513

 

 

 

3.9

%

Depreciation and amortization

 

 

44,731

 

 

 

3.4

%

 

 

45,090

 

 

 

3.5

%

Lease and rental expense

 

 

10,724

 

 

 

0.8

%

 

 

11,251

 

 

 

0.9

%

Subtotal-operating expenses

 

 

1,116,549

 

 

 

83.7

%

 

 

1,049,447

 

 

 

81.6

%

Income from operations

 

 

217,983

 

 

 

16.3

%

 

 

236,530

 

 

 

18.4

%

Interest expense, net

 

 

465

 

 

 

0.0

%

 

 

338

 

 

 

0.0

%

Other (income) expense, net

 

 

(115

)

 

 

(0.0

)%

 

 

413

 

 

 

0.0

%

Income before income taxes

 

$

217,633

 

 

 

16.3

%

 

$

235,779

 

 

 

18.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

All Behavioral Health Care Services

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

 

March 31, 2022

 

 

March 31, 2021

 

 

 

Amount

 

 

% of Net

Revenues

 

 

Amount

 

 

% of Net

Revenues

 

Net revenues

 

$

1,366,467

 

 

 

100.0

%

 

 

1,315,337

 

 

 

100.0

%

Operating charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

753,886

 

 

 

55.2

%

 

 

703,975

 

 

 

53.5

%

Other operating expenses

 

 

298,467

 

 

 

21.8

%

 

 

269,297

 

 

 

20.5

%

Supplies expense

 

 

50,178

 

 

 

3.7

%

 

 

51,009

 

 

 

3.9

%

Depreciation and amortization

 

 

46,079

 

 

 

3.4

%

 

 

46,482

 

 

 

3.5

%

Lease and rental expense

 

 

10,820

 

 

 

0.8

%

 

 

11,683

 

 

 

0.9

%

Subtotal-operating expenses

 

 

1,159,430

 

 

 

84.8

%

 

 

1,082,446

 

 

 

82.3

%

Income from operations

 

 

207,037

 

 

 

15.2

%

 

 

232,891

 

 

 

17.7

%

Interest expense, net

 

 

1,365

 

 

 

0.1

%

 

 

1,153

 

 

 

0.1

%

Other (income) expense, net

 

 

(115

)

 

 

(0.0

)%

 

 

413

 

 

 

0.0

%

Income before income taxes

 

$

205,787

 

 

 

15.1

%

 

$

231,325

 

 

 

17.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments, lawsuits and reserves established in connection with the government's investigation of our behavioral health care facilities, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and in the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2021.

 

The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months as well as the results of certain facilities that were closed or restructured during the past year.

 


 

Universal Health Services, Inc.

 

Selected Hospital Statistics

 

For the Three Months Ended

 

March 31, 2022 and 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AS REPORTED:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACUTE

 

 

BEHAVIORAL HEALTH

 

 

 

03/31/22

 

 

03/31/21

 

 

% change

 

 

03/31/22

 

 

03/31/21

 

 

% change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospitals owned and leased

 

 

27

 

 

 

26

 

 

 

3.8

%

 

 

336

 

 

 

335

 

 

 

0.3

%

Average licensed beds

 

 

6,749

 

 

 

6,515

 

 

 

3.6

%

 

 

24,243

 

 

 

24,018

 

 

 

0.9

%

Average available beds

 

 

6,577

 

 

 

6,343

 

 

 

3.7

%

 

 

24,143

 

 

 

23,918

 

 

 

0.9

%

Patient days

 

 

405,952

 

 

 

392,391

 

 

 

3.5

%

 

 

1,506,351

 

 

 

1,534,162

 

 

 

-1.8

%

Average daily census

 

 

4,510.6

 

 

 

4,359.9

 

 

 

3.5

%

 

 

16,737.2

 

 

 

17,046.2

 

 

 

-1.8

%

Occupancy-licensed beds

 

 

66.8

%

 

 

66.9

%

 

 

-0.1

%

 

 

69.0

%

 

 

71.0

%

 

 

-2.8

%

Occupancy-available beds

 

 

68.6

%

 

 

68.7

%

 

 

-0.2

%

 

 

69.3

%

 

 

71.3

%

 

 

-2.8

%

Admissions

 

 

75,289

 

 

 

72,924

 

 

 

3.2

%

 

 

112,433

 

 

 

115,408

 

 

 

-2.6

%

Length of stay

 

 

5.4

 

 

 

5.4

 

 

 

-0.1

%

 

 

13.4

 

 

 

13.3

 

 

 

0.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Inpatient revenue

 

$

10,239,231

 

 

$

9,119,184

 

 

 

12.3

%

 

$

2,436,474

 

 

$

2,473,565

 

 

 

-1.5

%

Outpatient revenue

 

 

5,775,539

 

 

 

4,580,720

 

 

 

26.1

%

 

 

257,113

 

 

 

246,764

 

 

 

4.2

%

Total patient revenue

 

 

16,014,770

 

 

 

13,699,904

 

 

 

16.9

%

 

 

2,693,587

 

 

 

2,720,329

 

 

 

-1.0

%

Other revenue

 

 

184,481

 

 

 

143,265

 

 

 

28.8

%

 

 

66,697

 

 

 

62,208

 

 

 

7.2

%

Gross hospital revenue

 

 

16,199,251

 

 

 

13,843,169

 

 

 

17.0

%

 

 

2,760,284

 

 

 

2,782,537

 

 

 

-0.8

%

Total deductions

 

 

14,286,935

 

 

 

12,148,627

 

 

 

17.6

%

 

 

1,393,817

 

 

 

1,467,200

 

 

 

-5.0

%

Net hospital revenue

 

$

1,912,316

 

 

$

1,694,542

 

 

 

12.9

%

 

$

1,366,467

 

 

$

1,315,337

 

 

 

3.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SAME FACILITY:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACUTE

 

 

BEHAVIORAL HEALTH

 

 

 

03/31/22

 

 

03/31/21

 

 

% change

 

 

03/31/22

 

 

03/31/21

 

 

% change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospitals owned and leased

 

 

26

 

 

 

26

 

 

 

0.0

%

 

 

331

 

 

 

331

 

 

 

0.0

%

Average licensed beds

 

 

6,683

 

 

 

6,515

 

 

 

2.6

%

 

 

23,841

 

 

 

23,725

 

 

 

0.5

%

Average available beds

 

 

6,511

 

 

 

6,343

 

 

 

2.6

%

 

 

23,741

 

 

 

23,625

 

 

 

0.5

%

Patient days

 

 

402,165

 

 

 

392,391

 

 

 

2.5

%

 

 

1,493,766

 

 

 

1,519,290

 

 

 

-1.7

%

Average daily census

 

 

4,468.5

 

 

 

4,359.9

 

 

 

2.5

%

 

 

16,597.4

 

 

 

16,881.0

 

 

 

-1.7

%

Occupancy-licensed beds

 

 

66.9

%

 

 

66.9

%

 

 

-0.1

%

 

 

69.6

%

 

 

71.2

%

 

 

-2.2

%

Occupancy-available beds

 

 

68.6

%

 

 

68.7

%

 

 

-0.2

%

 

 

69.9

%

 

 

71.5

%

 

 

-2.2

%

Admissions

 

 

74,933

 

 

 

72,924

 

 

 

2.8

%

 

 

111,084

 

 

 

113,708

 

 

 

-2.3

%

Length of stay

 

 

5.4

 

 

 

5.4

 

 

 

-0.3

%

 

 

13.4

 

 

 

13.4

 

 

 

0.6

%

 

 

 

 

 

 

 

 

 

 

 

EX-101.SCH 3 uhs-20220425.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 uhs-20220425_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 uhs-20220425_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 25, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 25, 2022
Entity Registrant Name UNIVERSAL HEALTH SERVICES, INC.
Entity Central Index Key 0000352915
Entity Emerging Growth Company false
Entity File Number 1-10765
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 23-2077891
Entity Address, Address Line One UNIVERSAL CORPORATE CENTER
Entity Address, Address Line Two 367 SOUTH GULPH ROAD
Entity Address, City or Town KING OF PRUSSIA
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19406
City Area Code 610
Local Phone Number 768-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Class B Common Stock
Trading Symbol UHS
Security Exchange Name NYSE
XML 7 uhs-8k_20220425_htm.xml IDEA: XBRL DOCUMENT 0000352915 2022-04-25 2022-04-25 false 0000352915 8-K 2022-04-25 UNIVERSAL HEALTH SERVICES, INC. DE 1-10765 23-2077891 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406 610 768-3300 false false false false Class B Common Stock UHS NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports uhs-8k_20220425.htm uhs-20220425.xsd uhs-20220425_lab.xml uhs-20220425_pre.xml uhs-ex991_6.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uhs-8k_20220425.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "uhs-8k_20220425.htm" ] }, "labelLink": { "local": [ "uhs-20220425_lab.xml" ] }, "presentationLink": { "local": [ "uhs-20220425_pre.xml" ] }, "schema": { "local": [ "uhs-20220425.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uhs", "nsuri": "http://www.uhsinc.com/20220425", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20220425.htm", "contextRef": "C_0000352915_20220425_20220425", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20220425.htm", "contextRef": "C_0000352915_20220425_20220425", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.uhsinc.com/20220425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-22-015520-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-015520-xbrl.zip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end